Orexo AB (ORX) - Total Assets
Based on the latest financial reports, Orexo AB (ORX) holds total assets worth Skr1.30 Billion SEK (≈ $140.20 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Orexo AB for net asset value and shareholders' equity analysis.
Orexo AB - Total Assets Trend (2002–2025)
This chart illustrates how Orexo AB's total assets have evolved over time, based on quarterly financial data.
Orexo AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Orexo AB's total assets of Skr1.30 Billion consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 70.0% |
| Accounts Receivable | Skr237.40 Million | 18.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr56.40 Million | 4.3% |
| Intangible Assets | Skr400.00K | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Orexo AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Orexo AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orexo AB's current assets represent 89.4% of total assets in 2025, an increase from 61.1% in 2002.
- Cash Position: Cash and equivalents constituted 70.0% of total assets in 2025, up from 44.7% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.
Orexo AB Competitors by Total Assets
Key competitors of Orexo AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Orexo AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.70 | 1.93 | 2.97 |
| Quick Ratio | 3.70 | 1.67 | 2.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr850.10 Million | Skr215.30 Million | Skr679.90 Million |
Orexo AB - Advanced Valuation Insights
This section examines the relationship between Orexo AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 119.0% |
| Total Assets | Skr1.30 Billion |
| Market Capitalization | $70.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orexo AB's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Orexo AB's assets grew by 119.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orexo AB (2002–2025)
The table below shows the annual total assets of Orexo AB from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.30 Billion ≈ $140.20 Million |
+119.03% |
| 2024-12-31 | Skr594.80 Million ≈ $64.01 Million |
-24.38% |
| 2023-12-31 | Skr786.60 Million ≈ $84.65 Million |
-29.07% |
| 2022-12-31 | Skr1.11 Billion ≈ $119.35 Million |
-12.93% |
| 2021-12-31 | Skr1.27 Billion ≈ $137.07 Million |
+3.31% |
| 2020-12-31 | Skr1.23 Billion ≈ $132.68 Million |
-17.87% |
| 2019-12-31 | Skr1.50 Billion ≈ $161.54 Million |
+16.66% |
| 2018-12-31 | Skr1.29 Billion ≈ $138.47 Million |
+28.17% |
| 2017-12-31 | Skr1.00 Billion ≈ $108.04 Million |
-1.46% |
| 2016-12-31 | Skr1.02 Billion ≈ $109.64 Million |
+0.25% |
| 2015-12-31 | Skr1.02 Billion ≈ $109.37 Million |
-17.10% |
| 2014-12-31 | Skr1.23 Billion ≈ $131.92 Million |
+58.73% |
| 2013-12-31 | Skr772.33 Million ≈ $83.12 Million |
+60.32% |
| 2012-12-31 | Skr481.75 Million ≈ $51.84 Million |
-11.78% |
| 2011-12-31 | Skr546.10 Million ≈ $58.77 Million |
-23.37% |
| 2010-12-31 | Skr712.69 Million ≈ $76.70 Million |
+9.76% |
| 2009-12-31 | Skr649.33 Million ≈ $69.88 Million |
-7.51% |
| 2008-12-31 | Skr702.02 Million ≈ $75.55 Million |
-12.45% |
| 2007-12-31 | Skr801.87 Million ≈ $86.29 Million |
+111.06% |
| 2006-12-31 | Skr379.93 Million ≈ $40.89 Million |
+2.32% |
| 2005-12-31 | Skr371.31 Million ≈ $39.96 Million |
+250.24% |
| 2004-12-31 | Skr106.02 Million ≈ $11.41 Million |
+134.80% |
| 2003-12-31 | Skr45.15 Million ≈ $4.86 Million |
+35.80% |
| 2002-12-31 | Skr33.25 Million ≈ $3.58 Million |
-- |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more